Crow Point Partners’s Immune Design Corp. IMDZ Stock Holding History

Crow Point Partners’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-38,324	Closed	-$132K	–	178
2018 Q3	$132K	Buy	38,324 +2,933	+8%	+$11K	0.02%	156
2018 Q2	$155K	Buy	35,391 +27,696	+360%	+$110K	0.03%	115
2018 Q1	$25K	Buy	7,695 +2,121	+38%	+$7.51K	﹤0.01%	238
2017 Q4	$23K	Buy	+5,574	New	+$30.4K	﹤0.01%	242

Other funds holding IMDZ

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Crow Point Partners's IMDZ Position: Q4 2018 in Review

Crow Point Partners sold out of Immune Design Corp. (IMDZ) in Q4 2018, closing a stake of 38,324 shares — an estimated $132K sold.

Crow Point Partners first reported a position in IMDZ in Q4 2017 and held it in 4 quarters. The position peaked at $155K in Q2 2018. 64 funds tracked by Wall St. Rank hold IMDZ as of Q4 2018.

Crow Point Partners reported no remaining Immune Design Corp. position as of Q4 2018 after selling out during the quarter.
Crow Point Partners sold 38,324 Immune Design Corp. shares in Q4 2018, an estimated $132K.
Crow Point Partners first reported a position in Immune Design Corp. in Q4 2017 and held it in 4 quarters.
Crow Point Partners's Immune Design Corp. position peaked at $155K in Q2 2018.
64 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2018.

Based on Crow Point Partners's 13F filing for Q4 2018, filed 14 Feb 2019.